Logo image of WLLW.CA

WILLOW BIOSCIENCES INC (WLLW.CA) Stock Fundamental Analysis

Canada - Toronto Stock Exchange - TSX:WLLW - CA97111B4047 - Common Stock

0.17 CAD
+0.01 (+6.25%)
Last: 10/3/2025, 7:00:00 PM
Fundamental Rating

1

Overall WLLW gets a fundamental rating of 1 out of 10. We evaluated WLLW against 23 industry peers in the Biotechnology industry. WLLW may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, WLLW is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

WLLW had negative earnings in the past year.
In the past year WLLW has reported a negative cash flow from operations.
WLLW had negative earnings in each of the past 5 years.
WLLW had a negative operating cash flow in each of the past 5 years.
WLLW.CA Yearly Net Income VS EBIT VS OCF VS FCFWLLW.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of WLLW (-179.33%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -179.33%
ROE N/A
ROIC N/A
ROA(3y)-175.17%
ROA(5y)-139.67%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
WLLW.CA Yearly ROA, ROE, ROICWLLW.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for WLLW so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
WLLW.CA Yearly Profit, Operating, Gross MarginsWLLW.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100K -200K -300K

More info and screens

1

2. Health

2.1 Basic Checks

WLLW does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, WLLW has more shares outstanding
The number of shares outstanding for WLLW has been increased compared to 5 years ago.
WLLW has a worse debt/assets ratio than last year.
WLLW.CA Yearly Shares OutstandingWLLW.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
WLLW.CA Yearly Total Debt VS Total AssetsWLLW.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -57.93, we must say that WLLW is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -57.93, WLLW is doing worse than 62.50% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -57.93
ROIC/WACCN/A
WACC8.82%
WLLW.CA Yearly LT Debt VS Equity VS FCFWLLW.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

WLLW has a Current Ratio of 1.01. This is a normal value and indicates that WLLW is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.01, WLLW perfoms like the industry average, outperforming 45.83% of the companies in the same industry.
A Quick Ratio of 1.01 indicates that WLLW should not have too much problems paying its short term obligations.
WLLW has a Quick ratio (1.01) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.01
Quick Ratio 1.01
WLLW.CA Yearly Current Assets VS Current LiabilitesWLLW.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 66.95% over the past year.
Looking at the last year, WLLW shows a very strong growth in Revenue. The Revenue has grown by 570.53%.
The Revenue has been growing by 229.77% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)66.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.56%
Revenue 1Y (TTM)570.53%
Revenue growth 3Y229.77%
Revenue growth 5YN/A
Sales Q2Q%3349.02%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
WLLW.CA Yearly Revenue VS EstimatesWLLW.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 1M 2M 3M 4M
WLLW.CA Yearly EPS VS EstimatesWLLW.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

WLLW reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
WLLW.CA Price Earnings VS Forward Price EarningsWLLW.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
WLLW.CA Per share dataWLLW.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.05 -0.1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for WLLW!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

WILLOW BIOSCIENCES INC

TSX:WLLW (10/3/2025, 7:00:00 PM)

0.17

+0.01 (+6.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11
Earnings (Next)11-10 2025-11-10
Inst Owners19.06%
Inst Owner ChangeN/A
Ins Owners39.31%
Ins Owner ChangeN/A
Market Cap107.00M
Revenue(TTM)6.37M
Net Income(TTM)-4.15M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.8
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.13
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0.01
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -179.33%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-175.17%
ROA(5y)-139.67%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover2.75
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.01
Quick Ratio 1.01
Altman-Z -57.93
F-Score4
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)20.3%
Cap/Depr(5y)29.57%
Cap/Sales(3y)45.39%
Cap/Sales(5y)2299.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.56%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)570.53%
Revenue growth 3Y229.77%
Revenue growth 5YN/A
Sales Q2Q%3349.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y71.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y86.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y85.21%
OCF growth 3YN/A
OCF growth 5YN/A

WILLOW BIOSCIENCES INC / WLLW.CA FAQ

What is the ChartMill fundamental rating of WILLOW BIOSCIENCES INC (WLLW.CA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to WLLW.CA.


Can you provide the valuation status for WILLOW BIOSCIENCES INC?

ChartMill assigns a valuation rating of 0 / 10 to WILLOW BIOSCIENCES INC (WLLW.CA). This can be considered as Overvalued.


What is the profitability of WLLW stock?

WILLOW BIOSCIENCES INC (WLLW.CA) has a profitability rating of 0 / 10.


How financially healthy is WILLOW BIOSCIENCES INC?

The financial health rating of WILLOW BIOSCIENCES INC (WLLW.CA) is 1 / 10.